Crossmark Global Holdings Inc. Sells 653 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Crossmark Global Holdings Inc. decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 18.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,976 shares of the biotechnology company’s stock after selling 653 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in United Therapeutics were worth $948,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Dimensional Fund Advisors LP raised its holdings in United Therapeutics by 1.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 561,950 shares of the biotechnology company’s stock valued at $123,566,000 after acquiring an additional 9,962 shares during the period. LSV Asset Management raised its holdings in United Therapeutics by 40.3% during the 1st quarter. LSV Asset Management now owns 529,519 shares of the biotechnology company’s stock valued at $121,641,000 after acquiring an additional 152,151 shares during the period. Norges Bank bought a new stake in United Therapeutics during the 4th quarter valued at $100,519,000. Swedbank AB bought a new stake in United Therapeutics during the 1st quarter valued at $97,316,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in United Therapeutics by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 319,030 shares of the biotechnology company’s stock valued at $70,152,000 after acquiring an additional 7,723 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $277.13, for a total transaction of $997,668.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $36,026.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $277.13, for a total transaction of $997,668.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $36,026.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Raymond Dwek sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $325.35, for a total value of $1,626,750.00. Following the transaction, the director now directly owns 1,750 shares in the company, valued at $569,362.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 115,335 shares of company stock valued at $36,748,759. 12.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, May 21st. HC Wainwright reiterated a “buy” rating and issued a $400.00 price objective on shares of United Therapeutics in a research report on Thursday, August 1st. Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Oppenheimer increased their price objective on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $350.36.

United Therapeutics Stock Up 0.9 %

UTHR opened at $363.55 on Friday. The stock has a market cap of $16.13 billion, a PE ratio of 17.19, a P/E/G ratio of 1.25 and a beta of 0.55. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $365.98. The business’s fifty day simple moving average is $330.38 and its 200 day simple moving average is $278.47.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The firm had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm’s revenue was up 19.8% compared to the same quarter last year. During the same period in the prior year, the company earned $5.24 EPS. As a group, research analysts expect that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.